| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 60 | 2022 | 555 | 13.660 |
Why?
|
| Prostatic Neoplasms | 177 | 2024 | 11124 | 6.740 |
Why?
|
| Periodicals as Topic | 22 | 2021 | 1432 | 5.340 |
Why?
|
| Urinary Bladder Neoplasms | 58 | 2023 | 2245 | 4.160 |
Why?
|
| Prostate-Specific Antigen | 72 | 2023 | 2494 | 3.830 |
Why?
|
| Bibliometrics | 10 | 2021 | 339 | 2.830 |
Why?
|
| Cystectomy | 37 | 2023 | 686 | 2.400 |
Why?
|
| Brachytherapy | 26 | 2022 | 1248 | 2.170 |
Why?
|
| Radiotherapy Dosage | 52 | 2016 | 2879 | 2.170 |
Why?
|
| Editorial Policies | 9 | 2021 | 451 | 1.990 |
Why?
|
| Carcinoma, Transitional Cell | 20 | 2023 | 808 | 1.930 |
Why?
|
| Radiotherapy, Conformal | 19 | 2015 | 548 | 1.920 |
Why?
|
| Information Storage and Retrieval | 6 | 2019 | 824 | 1.860 |
Why?
|
| Authorship | 7 | 2021 | 271 | 1.640 |
Why?
|
| Prostatectomy | 40 | 2023 | 1890 | 1.600 |
Why?
|
| Peer Review, Research | 6 | 2021 | 329 | 1.580 |
Why?
|
| Radiotherapy | 21 | 2020 | 1533 | 1.560 |
Why?
|
| Urinary Bladder | 22 | 2023 | 1172 | 1.560 |
Why?
|
| Adenocarcinoma | 34 | 2015 | 6364 | 1.550 |
Why?
|
| Androgen Antagonists | 25 | 2022 | 1377 | 1.540 |
Why?
|
| Publishing | 7 | 2021 | 833 | 1.440 |
Why?
|
| Radiotherapy, Intensity-Modulated | 16 | 2017 | 806 | 1.390 |
Why?
|
| Journal Impact Factor | 5 | 2018 | 156 | 1.370 |
Why?
|
| Salvage Therapy | 23 | 2020 | 1275 | 1.200 |
Why?
|
| Watchful Waiting | 10 | 2023 | 492 | 1.130 |
Why?
|
| Radiobiology | 3 | 2015 | 85 | 1.080 |
Why?
|
| Scientific Misconduct | 2 | 2017 | 71 | 1.020 |
Why?
|
| Combined Modality Therapy | 54 | 2020 | 8642 | 1.000 |
Why?
|
| Neoplasm Invasiveness | 40 | 2022 | 3616 | 0.990 |
Why?
|
| Publications | 2 | 2019 | 195 | 0.960 |
Why?
|
| Neoplasm Staging | 62 | 2020 | 11031 | 0.940 |
Why?
|
| Antineoplastic Agents, Hormonal | 14 | 2015 | 1524 | 0.900 |
Why?
|
| Muscle Neoplasms | 3 | 2013 | 139 | 0.870 |
Why?
|
| Medically Underserved Area | 2 | 2014 | 253 | 0.840 |
Why?
|
| Neoplasms | 22 | 2023 | 21683 | 0.840 |
Why?
|
| Dose-Response Relationship, Radiation | 15 | 2016 | 876 | 0.830 |
Why?
|
| Prostate | 21 | 2023 | 1774 | 0.800 |
Why?
|
| Guidelines as Topic | 3 | 2020 | 1405 | 0.790 |
Why?
|
| Chemotherapy, Adjuvant | 22 | 2020 | 3479 | 0.770 |
Why?
|
| Male | 231 | 2024 | 350118 | 0.760 |
Why?
|
| Radiosurgery | 6 | 2024 | 1329 | 0.740 |
Why?
|
| Humans | 300 | 2024 | 744343 | 0.730 |
Why?
|
| Protons | 8 | 2014 | 1127 | 0.730 |
Why?
|
| Forecasting | 7 | 2020 | 2951 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2023 | 11524 | 0.710 |
Why?
|
| Treatment Failure | 21 | 2016 | 2618 | 0.670 |
Why?
|
| Ablation Techniques | 3 | 2020 | 249 | 0.670 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2023 | 1624 | 0.670 |
Why?
|
| Evidence-Based Medicine | 11 | 2020 | 3610 | 0.660 |
Why?
|
| Radiotherapy, Adjuvant | 20 | 2020 | 1770 | 0.660 |
Why?
|
| Neoplasm Recurrence, Local | 35 | 2022 | 9239 | 0.660 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2017 | 6538 | 0.650 |
Why?
|
| Disease-Free Survival | 35 | 2017 | 6895 | 0.640 |
Why?
|
| Employment | 3 | 2016 | 1132 | 0.640 |
Why?
|
| Organs at Risk | 7 | 2017 | 346 | 0.620 |
Why?
|
| Physiological Phenomena | 1 | 2017 | 18 | 0.610 |
Why?
|
| Neoadjuvant Therapy | 11 | 2018 | 2728 | 0.600 |
Why?
|
| Publication Bias | 2 | 2015 | 162 | 0.590 |
Why?
|
| Neoplasm Metastasis | 13 | 2021 | 4851 | 0.580 |
Why?
|
| Specialty Boards | 2 | 2016 | 227 | 0.570 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2019 | 9959 | 0.570 |
Why?
|
| Technology, Radiologic | 3 | 2016 | 163 | 0.560 |
Why?
|
| Developing Countries | 6 | 2018 | 2815 | 0.550 |
Why?
|
| Internship and Residency | 4 | 2020 | 5788 | 0.550 |
Why?
|
| Rectum | 12 | 2017 | 904 | 0.540 |
Why?
|
| Peer Review | 2 | 2018 | 209 | 0.540 |
Why?
|
| Treatment Outcome | 66 | 2023 | 63114 | 0.530 |
Why?
|
| Foreign Medical Graduates | 1 | 2016 | 79 | 0.520 |
Why?
|
| Urination Disorders | 4 | 2016 | 241 | 0.500 |
Why?
|
| Conflict of Interest | 1 | 2019 | 544 | 0.480 |
Why?
|
| Muscle, Smooth | 7 | 2014 | 934 | 0.480 |
Why?
|
| Paclitaxel | 6 | 2023 | 1708 | 0.480 |
Why?
|
| Immunity | 1 | 2020 | 1012 | 0.480 |
Why?
|
| Internationality | 1 | 2020 | 1003 | 0.480 |
Why?
|
| Physics | 1 | 2014 | 87 | 0.480 |
Why?
|
| Aged | 111 | 2023 | 163280 | 0.470 |
Why?
|
| Health Care Costs | 4 | 2015 | 3209 | 0.460 |
Why?
|
| Quality of Life | 18 | 2017 | 12804 | 0.460 |
Why?
|
| Carcinoma, Ductal | 2 | 2013 | 101 | 0.460 |
Why?
|
| Seminoma | 4 | 2019 | 137 | 0.460 |
Why?
|
| Ethics, Professional | 1 | 2013 | 102 | 0.450 |
Why?
|
| Disclosure | 1 | 2019 | 736 | 0.450 |
Why?
|
| Consensus | 7 | 2020 | 2959 | 0.450 |
Why?
|
| Double-Blind Method | 4 | 2020 | 12026 | 0.450 |
Why?
|
| Cancer Care Facilities | 5 | 2016 | 402 | 0.440 |
Why?
|
| Urologic Surgical Procedures | 5 | 2018 | 302 | 0.430 |
Why?
|
| Certification | 1 | 2016 | 424 | 0.430 |
Why?
|
| Radiation Injuries | 8 | 2017 | 1180 | 0.430 |
Why?
|
| Testicular Neoplasms | 6 | 2019 | 804 | 0.420 |
Why?
|
| Orchiectomy | 8 | 2019 | 474 | 0.420 |
Why?
|
| Postoperative Care | 5 | 2018 | 1486 | 0.420 |
Why?
|
| Models, Economic | 1 | 2016 | 713 | 0.410 |
Why?
|
| Disasters | 1 | 2018 | 511 | 0.410 |
Why?
|
| Ethics, Research | 1 | 2013 | 191 | 0.410 |
Why?
|
| Disaster Planning | 1 | 2018 | 549 | 0.410 |
Why?
|
| Terminology as Topic | 2 | 2016 | 1547 | 0.410 |
Why?
|
| Diffusion of Innovation | 4 | 2019 | 725 | 0.380 |
Why?
|
| Technology Transfer | 1 | 2010 | 44 | 0.370 |
Why?
|
| Carcinoma | 5 | 2017 | 2375 | 0.370 |
Why?
|
| Awards and Prizes | 1 | 2015 | 375 | 0.370 |
Why?
|
| Middle Aged | 101 | 2023 | 213383 | 0.360 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2010 | 415 | 0.360 |
Why?
|
| Neoplasms, Experimental | 7 | 1997 | 1276 | 0.360 |
Why?
|
| Urology | 6 | 2020 | 399 | 0.350 |
Why?
|
| Leuprolide | 6 | 2011 | 321 | 0.350 |
Why?
|
| Societies, Medical | 8 | 2020 | 3743 | 0.350 |
Why?
|
| Aged, 80 and over | 44 | 2020 | 57776 | 0.350 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2012 | 306 | 0.350 |
Why?
|
| Medicine | 2 | 2016 | 946 | 0.340 |
Why?
|
| Quality Improvement | 3 | 2021 | 3749 | 0.340 |
Why?
|
| Attitude | 1 | 2014 | 776 | 0.340 |
Why?
|
| Program Development | 1 | 2015 | 1316 | 0.340 |
Why?
|
| Biomedical Research | 5 | 2018 | 3309 | 0.330 |
Why?
|
| Hospitals, General | 2 | 2017 | 749 | 0.320 |
Why?
|
| Follow-Up Studies | 43 | 2021 | 39050 | 0.320 |
Why?
|
| Cisplatin | 11 | 2023 | 1662 | 0.310 |
Why?
|
| Cystoscopy | 5 | 2006 | 134 | 0.310 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 1061 | 0.310 |
Why?
|
| Relative Biological Effectiveness | 4 | 2017 | 323 | 0.310 |
Why?
|
| Internet | 1 | 2019 | 3064 | 0.300 |
Why?
|
| Lymphoma | 3 | 2015 | 1877 | 0.300 |
Why?
|
| Pelvis | 9 | 2017 | 730 | 0.290 |
Why?
|
| History, 20th Century | 4 | 2019 | 2740 | 0.290 |
Why?
|
| Survival Rate | 24 | 2017 | 12788 | 0.280 |
Why?
|
| Time Factors | 28 | 2017 | 40075 | 0.280 |
Why?
|
| Biopsy | 18 | 2023 | 6756 | 0.280 |
Why?
|
| Multivariate Analysis | 20 | 2017 | 12245 | 0.280 |
Why?
|
| Plagiarism | 2 | 2017 | 22 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 3923 | 0.270 |
Why?
|
| Clinical Trials as Topic | 7 | 2018 | 7913 | 0.270 |
Why?
|
| BCG Vaccine | 1 | 2008 | 369 | 0.270 |
Why?
|
| Neoplasm Transplantation | 13 | 1997 | 2085 | 0.270 |
Why?
|
| Actuarial Analysis | 8 | 2004 | 378 | 0.260 |
Why?
|
| Early Detection of Cancer | 4 | 2015 | 3086 | 0.260 |
Why?
|
| Urodynamics | 2 | 2003 | 347 | 0.250 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 719 | 0.250 |
Why?
|
| Physicians | 1 | 2023 | 4567 | 0.240 |
Why?
|
| Self Report | 2 | 2015 | 3558 | 0.240 |
Why?
|
| Patient Selection | 12 | 2017 | 4215 | 0.230 |
Why?
|
| Medical Oncology | 4 | 2020 | 2265 | 0.230 |
Why?
|
| Urinary Bladder Diseases | 2 | 2003 | 166 | 0.230 |
Why?
|
| Disease Progression | 9 | 2023 | 13284 | 0.220 |
Why?
|
| History, 21st Century | 2 | 2019 | 1534 | 0.220 |
Why?
|
| United States | 28 | 2022 | 69872 | 0.220 |
Why?
|
| Radiometry | 5 | 2017 | 800 | 0.220 |
Why?
|
| Mice, Nude | 13 | 2005 | 3689 | 0.210 |
Why?
|
| Urinary Retention | 1 | 2003 | 111 | 0.210 |
Why?
|
| Medical Illustration | 2 | 2013 | 133 | 0.200 |
Why?
|
| Radiotherapy, High-Energy | 5 | 2007 | 228 | 0.200 |
Why?
|
| Androgens | 3 | 2021 | 1281 | 0.200 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2022 | 83 | 0.200 |
Why?
|
| Proportional Hazards Models | 11 | 2017 | 12354 | 0.200 |
Why?
|
| Survivors | 3 | 2017 | 2291 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 8 | 2020 | 7279 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 5 | 2013 | 358 | 0.190 |
Why?
|
| Urethra | 7 | 2022 | 408 | 0.190 |
Why?
|
| Pathology, Clinical | 2 | 2014 | 368 | 0.190 |
Why?
|
| Sex Reassignment Surgery | 1 | 2023 | 130 | 0.190 |
Why?
|
| Clinical Competence | 1 | 2016 | 4687 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 5 | 2015 | 2716 | 0.180 |
Why?
|
| Mass Screening | 2 | 2013 | 5255 | 0.180 |
Why?
|
| Survival Analysis | 12 | 2017 | 10252 | 0.180 |
Why?
|
| Lymph Nodes | 7 | 2017 | 3474 | 0.180 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 1956 | 0.180 |
Why?
|
| Nomograms | 2 | 2013 | 228 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2014 | 841 | 0.170 |
Why?
|
| Prognosis | 21 | 2020 | 29063 | 0.170 |
Why?
|
| Muscles | 5 | 2023 | 1614 | 0.170 |
Why?
|
| Anilides | 2 | 2017 | 408 | 0.170 |
Why?
|
| Antineoplastic Agents | 11 | 2019 | 13695 | 0.160 |
Why?
|
| Fluorouracil | 4 | 2018 | 1619 | 0.160 |
Why?
|
| Tumor Burden | 5 | 2014 | 1915 | 0.160 |
Why?
|
| Movement | 3 | 2016 | 1471 | 0.160 |
Why?
|
| Risk Factors | 21 | 2023 | 72290 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 506 | 0.160 |
Why?
|
| Tosyl Compounds | 2 | 2017 | 113 | 0.160 |
Why?
|
| Quarantine | 1 | 2020 | 170 | 0.160 |
Why?
|
| Career Choice | 2 | 2016 | 744 | 0.160 |
Why?
|
| Radiography | 5 | 2018 | 7023 | 0.150 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15295 | 0.150 |
Why?
|
| Seminal Vesicles | 6 | 2016 | 101 | 0.150 |
Why?
|
| Tsunamis | 1 | 2018 | 59 | 0.150 |
Why?
|
| Lymphatic Metastasis | 8 | 2017 | 2924 | 0.150 |
Why?
|
| Lymphatic Irradiation | 2 | 2008 | 103 | 0.150 |
Why?
|
| Deoxycytidine | 2 | 2018 | 826 | 0.150 |
Why?
|
| Fraud | 1 | 2017 | 67 | 0.150 |
Why?
|
| Texas | 1 | 2018 | 392 | 0.150 |
Why?
|
| Female | 49 | 2023 | 380194 | 0.150 |
Why?
|
| Puerto Rico | 1 | 2018 | 356 | 0.150 |
Why?
|
| X-Ray Therapy | 1 | 2016 | 9 | 0.150 |
Why?
|
| Retrospective Studies | 30 | 2023 | 77449 | 0.140 |
Why?
|
| Career Mobility | 1 | 2019 | 262 | 0.140 |
Why?
|
| Risk | 6 | 2020 | 9687 | 0.140 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2016 | 27 | 0.140 |
Why?
|
| Abortion, Induced | 1 | 2022 | 458 | 0.140 |
Why?
|
| Relief Work | 1 | 2018 | 137 | 0.140 |
Why?
|
| Adult | 35 | 2022 | 214055 | 0.140 |
Why?
|
| Cyclonic Storms | 1 | 2018 | 119 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 6773 | 0.140 |
Why?
|
| Hematuria | 3 | 2013 | 235 | 0.140 |
Why?
|
| Predictive Value of Tests | 8 | 2016 | 15076 | 0.140 |
Why?
|
| Risk Assessment | 7 | 2021 | 23338 | 0.140 |
Why?
|
| Osteoporosis | 3 | 2020 | 1580 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2003 | 1951 | 0.130 |
Why?
|
| Paris | 1 | 2015 | 42 | 0.130 |
Why?
|
| Correspondence as Topic | 1 | 2015 | 27 | 0.130 |
Why?
|
| Osteoporotic Fractures | 1 | 2020 | 401 | 0.130 |
Why?
|
| Hodgkin Disease | 2 | 2015 | 1415 | 0.130 |
Why?
|
| Procarbazine | 1 | 2015 | 181 | 0.130 |
Why?
|
| Mechlorethamine | 1 | 2015 | 136 | 0.130 |
Why?
|
| Earthquakes | 1 | 2018 | 179 | 0.130 |
Why?
|
| Information Management | 1 | 2015 | 101 | 0.130 |
Why?
|
| Competitive Behavior | 1 | 2015 | 74 | 0.130 |
Why?
|
| Rectal Neoplasms | 2 | 2008 | 1206 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 3 | 2014 | 1677 | 0.130 |
Why?
|
| Paintings | 1 | 2016 | 101 | 0.130 |
Why?
|
| Cohort Studies | 13 | 2023 | 40561 | 0.130 |
Why?
|
| Deception | 1 | 2015 | 99 | 0.130 |
Why?
|
| Research | 3 | 2013 | 1999 | 0.130 |
Why?
|
| Reimbursement Mechanisms | 2 | 2012 | 670 | 0.130 |
Why?
|
| School Admission Criteria | 1 | 2015 | 105 | 0.120 |
Why?
|
| Urothelium | 1 | 2016 | 277 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2010 | 12720 | 0.120 |
Why?
|
| PubMed | 1 | 2015 | 123 | 0.120 |
Why?
|
| Community Health Centers | 1 | 2017 | 430 | 0.120 |
Why?
|
| Retraction of Publication as Topic | 1 | 2013 | 10 | 0.120 |
Why?
|
| Sensitivity and Specificity | 10 | 2016 | 14722 | 0.120 |
Why?
|
| Advisory Committees | 2 | 2015 | 775 | 0.120 |
Why?
|
| Japan | 1 | 2018 | 1360 | 0.120 |
Why?
|
| Photons | 3 | 2012 | 588 | 0.120 |
Why?
|
| Urinary Incontinence | 4 | 2015 | 496 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2003 | 2107 | 0.110 |
Why?
|
| Testosterone | 2 | 2002 | 2420 | 0.110 |
Why?
|
| Health Services Needs and Demand | 2 | 2014 | 1411 | 0.110 |
Why?
|
| Biological Science Disciplines | 1 | 2013 | 52 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2016 | 1130 | 0.110 |
Why?
|
| Urinary Catheterization | 1 | 2014 | 202 | 0.110 |
Why?
|
| Nitriles | 2 | 2017 | 956 | 0.110 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2015 | 286 | 0.110 |
Why?
|
| Vincristine | 1 | 2015 | 1039 | 0.110 |
Why?
|
| New York City | 1 | 2015 | 710 | 0.110 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2012 | 547 | 0.110 |
Why?
|
| Selection Bias | 1 | 2014 | 371 | 0.110 |
Why?
|
| History, 19th Century | 1 | 2015 | 720 | 0.110 |
Why?
|
| Age Factors | 12 | 2019 | 18370 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2010 | 1086 | 0.110 |
Why?
|
| Program Evaluation | 3 | 2016 | 2488 | 0.110 |
Why?
|
| Intestinal Diseases | 4 | 2016 | 530 | 0.110 |
Why?
|
| Radiation Dosage | 3 | 2017 | 1928 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2007 | 624 | 0.100 |
Why?
|
| Developed Countries | 3 | 2022 | 437 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 629 | 0.100 |
Why?
|
| Prospective Studies | 12 | 2022 | 53288 | 0.100 |
Why?
|
| Public Policy | 1 | 2016 | 572 | 0.100 |
Why?
|
| Pathology | 1 | 2015 | 272 | 0.100 |
Why?
|
| Catheters, Indwelling | 1 | 2014 | 426 | 0.100 |
Why?
|
| Writing | 1 | 2013 | 206 | 0.100 |
Why?
|
| Professional Role | 1 | 2014 | 306 | 0.100 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 19905 | 0.100 |
Why?
|
| Urinary Diversion | 2 | 2017 | 138 | 0.100 |
Why?
|
| Urethral Neoplasms | 1 | 2011 | 40 | 0.100 |
Why?
|
| Reference Standards | 2 | 2005 | 1025 | 0.100 |
Why?
|
| Mice, Inbred C3H | 6 | 1994 | 964 | 0.100 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 336 | 0.100 |
Why?
|
| Breast Neoplasms | 4 | 2015 | 20822 | 0.090 |
Why?
|
| Analysis of Variance | 6 | 2013 | 6365 | 0.090 |
Why?
|
| Digital Rectal Examination | 1 | 2010 | 42 | 0.090 |
Why?
|
| Urogenital System | 1 | 2010 | 86 | 0.090 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 695 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2015 | 764 | 0.090 |
Why?
|
| Prednisone | 1 | 2015 | 1574 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2012 | 2453 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2008 | 1205 | 0.090 |
Why?
|
| Pelvic Bones | 2 | 2010 | 265 | 0.090 |
Why?
|
| Radiology | 2 | 2016 | 2100 | 0.090 |
Why?
|
| Organ Size | 2 | 2015 | 2252 | 0.090 |
Why?
|
| Sexual Dysfunction, Physiological | 4 | 2016 | 360 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 2 | 2012 | 1486 | 0.090 |
Why?
|
| Immobilization | 1 | 2010 | 236 | 0.090 |
Why?
|
| Transplantation, Heterologous | 7 | 1993 | 2382 | 0.090 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 5319 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2011 | 1842 | 0.080 |
Why?
|
| Femur | 3 | 2012 | 1297 | 0.080 |
Why?
|
| Ethics, Clinical | 1 | 2009 | 101 | 0.080 |
Why?
|
| Palladium | 3 | 2011 | 65 | 0.080 |
Why?
|
| Rotation | 1 | 2010 | 523 | 0.080 |
Why?
|
| Information Dissemination | 2 | 2015 | 1099 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 500 | 0.080 |
Why?
|
| Propensity Score | 3 | 2023 | 1781 | 0.080 |
Why?
|
| SEER Program | 4 | 2019 | 1508 | 0.080 |
Why?
|
| Remission Induction | 6 | 2015 | 2386 | 0.080 |
Why?
|
| Boston | 4 | 2017 | 9313 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 1381 | 0.080 |
Why?
|
| Necrosis | 1 | 2012 | 1643 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 681 | 0.080 |
Why?
|
| Iodine Radioisotopes | 4 | 2011 | 1032 | 0.080 |
Why?
|
| Cost Control | 1 | 2010 | 624 | 0.080 |
Why?
|
| Oxides | 1 | 2009 | 405 | 0.080 |
Why?
|
| Radioisotopes | 3 | 2011 | 499 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 975 | 0.070 |
Why?
|
| Fibrosarcoma | 4 | 1993 | 348 | 0.070 |
Why?
|
| Subcutaneous Fat | 1 | 2010 | 391 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2014 | 9849 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 5137 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2012 | 4034 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 950 | 0.070 |
Why?
|
| Pregnancy | 2 | 2022 | 29144 | 0.070 |
Why?
|
| Guideline Adherence | 2 | 2013 | 2266 | 0.070 |
Why?
|
| Body Composition | 3 | 2008 | 2401 | 0.070 |
Why?
|
| Radionuclide Imaging | 4 | 2012 | 2031 | 0.070 |
Why?
|
| Biomedical Technology | 1 | 2008 | 220 | 0.070 |
Why?
|
| Incidence | 6 | 2017 | 20947 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2727 | 0.070 |
Why?
|
| Spermatic Cord | 2 | 1996 | 25 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1364 | 0.060 |
Why?
|
| Mice | 20 | 2010 | 81183 | 0.060 |
Why?
|
| Bone Neoplasms | 3 | 2011 | 2529 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 2212 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2008 | 6459 | 0.060 |
Why?
|
| Particle Size | 1 | 2009 | 1642 | 0.060 |
Why?
|
| Genital Neoplasms, Male | 2 | 1996 | 74 | 0.060 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 1261 | 0.060 |
Why?
|
| Sperm Count | 1 | 2005 | 216 | 0.060 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 2886 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 1351 | 0.060 |
Why?
|
| International Agencies | 2 | 2015 | 240 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2010 | 814 | 0.060 |
Why?
|
| Doxorubicin | 1 | 1991 | 2234 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 3507 | 0.060 |
Why?
|
| Education, Medical | 1 | 2016 | 1721 | 0.060 |
Why?
|
| Algorithms | 5 | 2018 | 13881 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1584 | 0.060 |
Why?
|
| Income | 1 | 2012 | 1913 | 0.060 |
Why?
|
| Ureteral Neoplasms | 1 | 2004 | 111 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2004 | 188 | 0.060 |
Why?
|
| Neoplasm, Residual | 3 | 2004 | 973 | 0.060 |
Why?
|
| Specialization | 1 | 2008 | 777 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 2012 | 2734 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2014 | 4262 | 0.060 |
Why?
|
| Decision Making | 2 | 2016 | 3887 | 0.060 |
Why?
|
| Triacetoneamine-N-Oxyl | 1 | 2022 | 5 | 0.060 |
Why?
|
| Longevity | 1 | 1991 | 1070 | 0.050 |
Why?
|
| Penis | 2 | 2016 | 216 | 0.050 |
Why?
|
| Patient Participation | 1 | 2012 | 1457 | 0.050 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2012 | 1209 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 1997 | 6314 | 0.050 |
Why?
|
| Germinoma | 1 | 2003 | 133 | 0.050 |
Why?
|
| Equipment Design | 1 | 2010 | 3582 | 0.050 |
Why?
|
| Erectile Dysfunction | 3 | 2007 | 461 | 0.050 |
Why?
|
| Life Tables | 1 | 2002 | 370 | 0.050 |
Why?
|
| Mediastinum | 1 | 2003 | 267 | 0.050 |
Why?
|
| Antineoplastic Protocols | 1 | 2001 | 50 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2017 | 20129 | 0.050 |
Why?
|
| Diagnosis, Differential | 5 | 2022 | 12959 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2012 | 2684 | 0.050 |
Why?
|
| Databases, Factual | 3 | 2019 | 7729 | 0.050 |
Why?
|
| Clinical Protocols | 3 | 1998 | 1462 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2005 | 1099 | 0.050 |
Why?
|
| Neoplasm Proteins | 3 | 2010 | 3703 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2007 | 1683 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2012 | 2531 | 0.050 |
Why?
|
| Iron | 1 | 2009 | 1774 | 0.050 |
Why?
|
| Nanoparticles | 2 | 2009 | 1905 | 0.050 |
Why?
|
| Data Collection | 1 | 2010 | 3341 | 0.050 |
Why?
|
| Anal Canal | 1 | 2023 | 376 | 0.050 |
Why?
|
| Thymosin | 1 | 2000 | 47 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2014 | 35421 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 2 | 2002 | 1376 | 0.050 |
Why?
|
| Animals | 20 | 2010 | 168757 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 3158 | 0.050 |
Why?
|
| Benchmarking | 1 | 2007 | 1042 | 0.050 |
Why?
|
| Diphosphonates | 2 | 2002 | 623 | 0.040 |
Why?
|
| Bone Density | 2 | 2004 | 3468 | 0.040 |
Why?
|
| Reference Values | 2 | 2005 | 4982 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 423 | 0.040 |
Why?
|
| Radioactive Hazard Release | 1 | 2019 | 14 | 0.040 |
Why?
|
| Intestines | 2 | 2012 | 1924 | 0.040 |
Why?
|
| Whole-Body Irradiation | 3 | 1990 | 449 | 0.040 |
Why?
|
| Medical Audit | 1 | 2021 | 467 | 0.040 |
Why?
|
| State Medicine | 1 | 2021 | 217 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 3508 | 0.040 |
Why?
|
| Medical Informatics | 2 | 2019 | 745 | 0.040 |
Why?
|
| Health Care Sector | 1 | 2021 | 194 | 0.040 |
Why?
|
| Mucins | 1 | 2022 | 564 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 1681 | 0.040 |
Why?
|
| Glioma | 2 | 1991 | 3401 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 520 | 0.040 |
Why?
|
| Edema | 1 | 2003 | 789 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 3143 | 0.040 |
Why?
|
| Research Support as Topic | 2 | 2013 | 705 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 2013 | 675 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2009 | 2921 | 0.040 |
Why?
|
| Comorbidity | 3 | 2015 | 10388 | 0.040 |
Why?
|
| Hormones | 1 | 2022 | 889 | 0.040 |
Why?
|
| Sample Size | 2 | 2016 | 845 | 0.040 |
Why?
|
| Vagina | 1 | 2023 | 825 | 0.040 |
Why?
|
| Hydronephrosis | 2 | 2013 | 269 | 0.040 |
Why?
|
| Strontium Radioisotopes | 1 | 1997 | 18 | 0.040 |
Why?
|
| Hydrogels | 1 | 2023 | 724 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1998 | 417 | 0.040 |
Why?
|
| Registries | 1 | 2013 | 8089 | 0.040 |
Why?
|
| Medical Informatics Applications | 1 | 2019 | 186 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 1059 | 0.040 |
Why?
|
| Posters as Topic | 1 | 2016 | 6 | 0.040 |
Why?
|
| Folklore | 1 | 2016 | 7 | 0.040 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2010 | 215 | 0.040 |
Why?
|
| Biology | 1 | 2019 | 294 | 0.040 |
Why?
|
| Apoptosis | 3 | 2005 | 9727 | 0.040 |
Why?
|
| Urethral Stricture | 2 | 1995 | 51 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2018 | 256 | 0.040 |
Why?
|
| Medicine in Literature | 1 | 2016 | 31 | 0.040 |
Why?
|
| Gynecomastia | 1 | 2017 | 88 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 1998 | 684 | 0.030 |
Why?
|
| Bone Marrow Neoplasms | 1 | 1997 | 104 | 0.030 |
Why?
|
| Radium | 1 | 2016 | 65 | 0.030 |
Why?
|
| Disease Management | 2 | 2018 | 2459 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2002 | 806 | 0.030 |
Why?
|
| Carboplatin | 1 | 2019 | 801 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2014 | 1641 | 0.030 |
Why?
|
| Death Certificates | 1 | 2016 | 169 | 0.030 |
Why?
|
| Rural Health Services | 1 | 2019 | 379 | 0.030 |
Why?
|
| Referral and Consultation | 4 | 2013 | 3528 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2008 | 6234 | 0.030 |
Why?
|
| Rectal Diseases | 2 | 2013 | 143 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 104 | 0.030 |
Why?
|
| Cause of Death | 2 | 2016 | 3584 | 0.030 |
Why?
|
| Recurrence | 1 | 2007 | 8340 | 0.030 |
Why?
|
| Linear Energy Transfer | 1 | 2016 | 154 | 0.030 |
Why?
|
| Voluntary Health Agencies | 1 | 2014 | 39 | 0.030 |
Why?
|
| Fiducial Markers | 1 | 2015 | 136 | 0.030 |
Why?
|
| Vas Deferens | 2 | 2009 | 55 | 0.030 |
Why?
|
| New Zealand | 1 | 2014 | 355 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2015 | 2616 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 25043 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 673 | 0.030 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 90 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2014 | 220 | 0.030 |
Why?
|
| S Phase | 1 | 1994 | 423 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2013 | 2971 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 248 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2009 | 2250 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2005 | 5172 | 0.030 |
Why?
|
| Capital Financing | 1 | 2012 | 58 | 0.030 |
Why?
|
| Adnexa Uteri | 1 | 2012 | 45 | 0.030 |
Why?
|
| Epididymis | 1 | 1994 | 227 | 0.030 |
Why?
|
| Inflammation | 1 | 2012 | 10638 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2013 | 270 | 0.030 |
Why?
|
| Mice, SCID | 3 | 2010 | 2716 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 573 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3255 | 0.030 |
Why?
|
| Lipoproteins | 2 | 2002 | 878 | 0.020 |
Why?
|
| Concanavalin A | 1 | 1991 | 191 | 0.020 |
Why?
|
| Cell Line | 5 | 1993 | 15997 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2012 | 455 | 0.020 |
Why?
|
| Decision Trees | 1 | 2013 | 506 | 0.020 |
Why?
|
| Marital Status | 1 | 2012 | 437 | 0.020 |
Why?
|
| Rats | 2 | 2000 | 24260 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 1254 | 0.020 |
Why?
|
| Cell Migration Assays | 1 | 2010 | 23 | 0.020 |
Why?
|
| Ribs | 1 | 2012 | 252 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2008 | 3760 | 0.020 |
Why?
|
| Fecal Incontinence | 1 | 2013 | 239 | 0.020 |
Why?
|
| Colic | 1 | 2010 | 42 | 0.020 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 1990 | 50 | 0.020 |
Why?
|
| Inverted Repeat Sequences | 1 | 2010 | 61 | 0.020 |
Why?
|
| Altruism | 1 | 2012 | 204 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 464 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 599 | 0.020 |
Why?
|
| Sarcoma | 3 | 1996 | 1897 | 0.020 |
Why?
|
| Pubic Symphysis | 1 | 2009 | 21 | 0.020 |
Why?
|
| Length of Stay | 1 | 2003 | 6309 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1988 | 5686 | 0.020 |
Why?
|
| Vinblastine | 2 | 2003 | 502 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1994 | 1758 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 690 | 0.020 |
Why?
|
| Faculty | 1 | 2012 | 386 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 1654 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 552 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 11366 | 0.020 |
Why?
|
| Defecation | 1 | 2010 | 188 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 1988 | 257 | 0.020 |
Why?
|
| Logistic Models | 2 | 2012 | 13408 | 0.020 |
Why?
|
| Ureter | 2 | 2004 | 375 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 1387 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 892 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 13102 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2014 | 1050 | 0.020 |
Why?
|
| Ferrosoferric Oxide | 1 | 2009 | 360 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1988 | 484 | 0.020 |
Why?
|
| Uterus | 1 | 2012 | 711 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2000 | 1912 | 0.020 |
Why?
|
| Fee-for-Service Plans | 1 | 2012 | 694 | 0.020 |
Why?
|
| Skull | 1 | 2012 | 813 | 0.020 |
Why?
|
| Ovary | 1 | 2012 | 981 | 0.020 |
Why?
|
| Magnetite Nanoparticles | 1 | 2009 | 321 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1988 | 8863 | 0.020 |
Why?
|
| Dextrans | 1 | 2009 | 595 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2000 | 2303 | 0.020 |
Why?
|
| California | 1 | 2011 | 1402 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15540 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2012 | 853 | 0.020 |
Why?
|
| Health Policy | 1 | 2019 | 2661 | 0.020 |
Why?
|
| Reimbursement, Incentive | 1 | 2012 | 540 | 0.020 |
Why?
|
| Cell Survival | 1 | 1997 | 5882 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1997 | 2948 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2008 | 438 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2013 | 828 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 972 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2011 | 21746 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 26385 | 0.020 |
Why?
|
| Urologic Diseases | 1 | 2008 | 244 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2001 | 4371 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1989 | 604 | 0.020 |
Why?
|
| Adolescent | 6 | 2014 | 85781 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 941 | 0.020 |
Why?
|
| Linear Models | 1 | 2015 | 5952 | 0.020 |
Why?
|
| Massachusetts | 2 | 2011 | 8663 | 0.020 |
Why?
|
| Minority Groups | 1 | 2012 | 1223 | 0.020 |
Why?
|
| Killer Cells, Natural | 2 | 1991 | 2133 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2013 | 8324 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2008 | 510 | 0.020 |
Why?
|
| Patient Preference | 1 | 2012 | 890 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2012 | 895 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 1994 | 5974 | 0.020 |
Why?
|
| DNA Repair | 1 | 2013 | 2046 | 0.010 |
Why?
|
| Palliative Care | 1 | 2019 | 3493 | 0.010 |
Why?
|
| Immunization | 1 | 1988 | 1256 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 1989 | 601 | 0.010 |
Why?
|
| Methotrexate | 2 | 2003 | 1727 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2010 | 1063 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1991 | 2216 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2012 | 2682 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 2282 | 0.010 |
Why?
|
| Lumbar Vertebrae | 2 | 2003 | 1848 | 0.010 |
Why?
|
| Diarrhea | 1 | 2010 | 1348 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2012 | 2050 | 0.010 |
Why?
|
| Research Design | 1 | 1998 | 5987 | 0.010 |
Why?
|
| Adiponectin | 1 | 2008 | 1100 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 928 | 0.010 |
Why?
|
| Motivation | 1 | 2012 | 1971 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3200 | 0.010 |
Why?
|
| Glioblastoma | 3 | 1993 | 3481 | 0.010 |
Why?
|
| Syndrome | 1 | 2008 | 3251 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1997 | 4445 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2278 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 3586 | 0.010 |
Why?
|
| Florida | 1 | 2002 | 435 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 16689 | 0.010 |
Why?
|
| Aspirin | 1 | 2013 | 3282 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2001 | 273 | 0.010 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 773 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 3508 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1988 | 1988 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 3396 | 0.010 |
Why?
|
| Stem Cells | 1 | 2013 | 3567 | 0.010 |
Why?
|
| Curriculum | 1 | 2013 | 3605 | 0.010 |
Why?
|
| Cryotherapy | 1 | 2001 | 155 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1988 | 4776 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1170 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1988 | 6386 | 0.010 |
Why?
|
| Medicaid | 1 | 2012 | 2736 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 2016 | 0.010 |
Why?
|
| False Negative Reactions | 2 | 1990 | 588 | 0.010 |
Why?
|
| Back Pain | 1 | 2003 | 545 | 0.010 |
Why?
|
| Software | 1 | 2013 | 4443 | 0.010 |
Why?
|
| Morbidity | 1 | 2004 | 1769 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 968 | 0.010 |
Why?
|
| Sex Factors | 1 | 2012 | 10397 | 0.010 |
Why?
|
| Leg | 1 | 2003 | 1116 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 2645 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 712 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2003 | 501 | 0.010 |
Why?
|
| Genomics | 1 | 2013 | 5720 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1991 | 4665 | 0.010 |
Why?
|
| Bone Resorption | 1 | 2001 | 723 | 0.010 |
Why?
|
| False Positive Reactions | 2 | 1990 | 981 | 0.010 |
Why?
|
| Heart | 1 | 1991 | 4467 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 760 | 0.010 |
Why?
|
| Lipids | 1 | 2008 | 3305 | 0.010 |
Why?
|
| Young Adult | 2 | 2014 | 56430 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 6489 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3778 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 4217 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 5300 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2002 | 1534 | 0.010 |
Why?
|
| Scrotum | 1 | 1996 | 115 | 0.010 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1996 | 109 | 0.010 |
Why?
|
| Neuroblastoma | 2 | 1993 | 1226 | 0.010 |
Why?
|
| Ureteral Obstruction | 1 | 1997 | 296 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1996 | 803 | 0.010 |
Why?
|
| Kidney | 1 | 1991 | 7186 | 0.010 |
Why?
|
| Pain | 2 | 2003 | 4986 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1996 | 299 | 0.010 |
Why?
|
| Physical Examination | 1 | 2001 | 1237 | 0.010 |
Why?
|
| Health Services Research | 1 | 2002 | 1836 | 0.010 |
Why?
|
| Cell Division | 2 | 1994 | 4568 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1990 | 10180 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3864 | 0.010 |
Why?
|
| Ploidies | 1 | 1994 | 281 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2001 | 1184 | 0.010 |
Why?
|
| Abdomen | 1 | 2000 | 1118 | 0.010 |
Why?
|
| Sclerosis | 1 | 1994 | 213 | 0.010 |
Why?
|
| Liposarcoma | 1 | 1996 | 333 | 0.010 |
Why?
|
| Safety | 1 | 1997 | 1186 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2008 | 8554 | 0.010 |
Why?
|
| Pelvic Neoplasms | 1 | 1994 | 254 | 0.010 |
Why?
|
| Lung | 1 | 1991 | 9856 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1996 | 477 | 0.010 |
Why?
|
| Colonic Neoplasms | 2 | 1993 | 2541 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 23403 | 0.010 |
Why?
|
| Deuterium | 1 | 1990 | 101 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2001 | 2575 | 0.010 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1990 | 117 | 0.010 |
Why?
|
| Mesothelioma | 1 | 1996 | 818 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1990 | 244 | 0.010 |
Why?
|
| Obesity | 1 | 2012 | 12745 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1989 | 172 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1989 | 322 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1994 | 1880 | 0.010 |
Why?
|
| Species Specificity | 1 | 1993 | 2478 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1997 | 1179 | 0.010 |
Why?
|
| Nitrates | 1 | 1990 | 265 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 3843 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1990 | 486 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 6171 | 0.000 |
Why?
|
| Child | 1 | 2012 | 77709 | 0.000 |
Why?
|
| Base Sequence | 1 | 1996 | 12797 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1995 | 3461 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 18111 | 0.000 |
Why?
|
| Triglycerides | 1 | 1990 | 2454 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 7722 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1989 | 2967 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1996 | 13033 | 0.000 |
Why?
|
| Macrophages | 1 | 1990 | 5655 | 0.000 |
Why?
|
| Models, Biological | 1 | 1990 | 9583 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1990 | 15165 | 0.000 |
Why?
|